Christopher Ellis

This profile gathers the share dealings of Christopher Ellis in Vaccitech plc, where the filings describe the role as senior executive. Over a trading history stretching from 4 May 2021 to 25 August 2022, the count stands at 16 filings.

Both buying and selling appear: 1 purchase worth €1,061, against 8 sales worth €309k. The net balance comes to €308k on the selling side. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 7 option exercises. 2022 to date brings no purchases and 8 sales.

The latest filing, published on 26 August 2022, reports an open-market sale of €2,158 in Vaccitech plc. The latest purchase dates back some time: it was published 1,995 days ago, on 6 May 2021. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.